Atrial Fibrillation

Pulmonary vein isolation was associated with genuine improvements in patients with atrial fibrillation at 6 months that cannot be attributed to a placebo effect, researchers reported at the European Society of Cardiology Congress.

Edoxaban monotherapy for patients with atrial fibrillation and stable coronary disease reduced risk for adverse clinical events, mainly driven by lower bleeding risk, compared with dual antiplatelet therapy, a speaker reported.

Treatment of atrial fibrillation with asundexian, a novel factor XIa inhibitor, was associated with increased stroke and systemic embolism risk despite lower bleeding risk compared with apixaban, a speaker reported.

Job strain and effort-reward imbalance in the workplace may put white-collar workers at increased risk for experiencing a heart arrhythmia, researchers reported.

The Care of the Athletic Heart Conference, held at Heart House in Washington, D.C., in early June, covered the entire scope of sports cardiology, with sessions tailored to new and seasoned sports cardiologists.

Cocoa flavanols may reduce the risk for incident atrial fibrillation over time, perhaps as a result of atrial remodeling, according to a secondary analysis of a completed study published in European Journal of Preventative Cardiology.

The American Heart Association’s PREVENT equations predicted that people with stage 1 hypertension have a lower 10-year risk for atherosclerotic CVD compared with the Pooled Cohort Equations.

Among patients with atrial fibrillation, those with wearable cardiac monitors had greater use of the health care system for AF purposes compared with those without wearables, researchers reported.